Clinical trial
Efficacy of Vaped Cannabidiol in Cannabis Use Disorder
NCT07933081 is registered in ClinicalTrials.gov with University Hospital, Bordeaux as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy of Vaped Cannabidiol in Cannabis Use Disorder
- Lead sponsor
- University Hospital, Bordeaux
- Phase
- Not applicable
- Overall status
- Not yet recruiting
- Start date
- January 31, 2027
- Completion date
- March 30, 2030
- Enrollment
- 242 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
cannabis use disorder
Arms
As registered; 2 arms.
-
Control group
The control group will use a placebo vape liquid with a choice of two flavors (cannabis or red berries)
-
Experimental group
The intervention group will use a CBD vape liquid at 70 mg/ml with a choice of two flavors (cannabis or red berries)
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Proportion of patients with a reduction of at least 50% in the total reported amount of cannabis consumed - 12 weeks
Proportion of patients for whom the intervention was successful, defined as a reduction of at least 50% in the total reported amount of cannabis consumed (in grams) at the end of the 12-week follow-up period, compared to baseline.
Lead sponsor's other trials
University Hospital, Bordeaux, most recent start first.
+801 more trials